Journal of Clinical & Experimental Nephrology

Significance of Renal Function Monitoring During Treatment with Abemaciclib

Treatment strategies for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer have changed in recent years. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are novel agents that directly block the activity of the cyclin D-CDK4/6 holoenzyme and prevent cell cycle progression from G1 to S phase by preventing the phosphorylation of retinoblastoma protein, which sequesters E2F family of transcription factors [1,2]. Among the various breast cancer subtypes, estrogen receptor-positive (ER+) breast cancer is the most sensitive to growth inhibition.

Author(s):

Ryoichi Matsunuma

Abstract | Full-Text | PDF

Share this